Literature DB >> 35400177

Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China.

Tingting Zhang1, Xia Yu1, Shu'an Wen1, Yi Xue1, Hua Xiao1, Ruyan Ren1, Fen Wang1, Lingling Dong1, Shibing Qin2, Hairong Huang1.   

Abstract

The cycloserine concentrations in plasma and bone that were collected during operations on 28 osteoarticular tuberculosis (TB) patients treated daily with a 500-mg cycloserine-containing regimen were determined. The median concentrations in plasma and bone were 16.29 μg/mL (interquartile range [IQR], 6.47 μg/mL) and 24.33 μg/g (IQR, 14.68 μg/g), respectively. The median bone/plasma penetration ratio was 0.76 (range, 0.33 to 1.98). Cycloserine could effectively penetrate bone and acquire concentrations comparable to those in plasma, which favors its usage in osteoarticular TB treatment.

Entities:  

Keywords:  bone; cycloserine; drug penetration; osteoarticular tuberculosis; plasma

Mesh:

Substances:

Year:  2022        PMID: 35400177      PMCID: PMC9112879          DOI: 10.1128/aac.02224-21

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.938


  17 in total

1.  Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China.

Authors:  Xia Yu; Xiling Zeng; Wenhui Shi; Yanjie Hu; Wenjuan Nie; Naihui Chu; Hairong Huang
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  Therapeutic drug monitoring in the treatment of tuberculosis: an update.

Authors:  Abdullah Alsultan; Charles A Peloquin
Journal:  Drugs       Date:  2014-06       Impact factor: 9.546

3.  d-Cycloserine Pharmacokinetics/Pharmacodynamics, Susceptibility, and Dosing Implications in Multidrug-resistant Tuberculosis: A Faustian Deal.

Authors:  Devyani Deshpande; Jan-Willem C Alffenaar; Claudio U Köser; Keertan Dheda; Moti L Chapagain; Noviana Simbar; Thomas Schön; Marieke G G Sturkenboom; Helen McIlleron; Pooi S Lee; Thearith Koeuth; Stellah G Mpagama; Sayera Banu; Suporn Foongladda; Oleg Ogarkov; Suporn Pholwat; Eric R Houpt; Scott K Heysell; Tawanda Gumbo
Journal:  Clin Infect Dis       Date:  2018-11-28       Impact factor: 9.079

4.  Serum concentrations of cycloserine and outcome of multidrug-resistant tuberculosis in Northern Taiwan.

Authors:  W-Y Hung; M-C Yu; Y-C Chiang; J-H Chang; C-Y Chiang; C-C Chang; H-C Chuang; K-J Bai
Journal:  Int J Tuberc Lung Dis       Date:  2014-05       Impact factor: 2.373

5.  Drug sensitivity patterns in Xpert-positive spinal tuberculosis: an observational study of 252 patients.

Authors:  Mihir Upadhyay; Jwalant Patel; Vishal Kundnani; Sameer Ruparel; Ankit Patel
Journal:  Eur Spine J       Date:  2020-02-13       Impact factor: 3.134

6.  Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone.

Authors:  Maxwell T Chirehwa; Richard Court; Mariana de Kock; Lubbe Wiesner; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Rob Warren; Paolo Denti; Helen McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

7.  Cycloserine Population Pharmacokinetics and Pharmacodynamics in Patients with Tuberculosis.

Authors:  Wael A Alghamdi; Abdullah Alsultan; Mohammad H Al-Shaer; Guohua An; Shahriar Ahmed; Yosra Alkabab; Sayera Banu; Ketevan Barbakadze; Eric Houpt; Maia Kipiani; Lali Mikiashvili; Stephan Schmidt; Scott K Heysell; Russell R Kempker; J Peter Cegielski; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

8.  Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes.

Authors:  Dimitrios Evangelopoulos; Gareth A Prosser; Angela Rodgers; Belinda M Dagg; Bhagwati Khatri; Mei Mei Ho; Maximiliano G Gutierrez; Teresa Cortes; Luiz Pedro S de Carvalho
Journal:  Nat Commun       Date:  2019-09-13       Impact factor: 14.919

9.  Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.

Authors:  Richard Court; Chad M Centner; Maxwell Chirehwa; Lubbe Wiesner; Paolo Denti; Nihal de Vries; Joseph Harding; Tawanda Gumbo; Gary Maartens; Helen McIlleron
Journal:  Int J Infect Dis       Date:  2021-03-05       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.